Artivion (NYSE:AORT) Now Covered by Analysts at Canaccord Genuity Group

Equities research analysts at Canaccord Genuity Group initiated coverage on shares of Artivion (NYSE:AORT - Get Free Report) in a research report issued on Tuesday, Marketbeat.com reports. The firm set a "buy" rating and a $35.00 price target on the stock. Canaccord Genuity Group's target price points to a potential upside of 15.52% from the stock's current price.

A number of other equities analysts have also issued reports on the stock. Citizens Jmp raised shares of Artivion to a "strong-buy" rating in a research report on Tuesday, May 6th. Stifel Nicolaus reduced their target price on shares of Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a report on Tuesday, February 25th. JMP Securities restated a "market outperform" rating and set a $33.00 target price on shares of Artivion in a research report on Tuesday, May 6th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 price target on shares of Artivion in a research report on Tuesday, May 6th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $32.00.

Artivion Stock Performance

Shares of NYSE:AORT traded up $0.60 on Tuesday, hitting $30.30. 549,608 shares of the company were exchanged, compared to its average volume of 337,831. The firm has a market capitalization of $1.29 billion, a P/E ratio of -60.60 and a beta of 1.62. The company has a current ratio of 5.53, a quick ratio of 3.95 and a debt-to-equity ratio of 1.08. Artivion has a 1-year low of $21.97 and a 1-year high of $32.33. The stock's 50 day moving average price is $27.07 and its 200 day moving average price is $27.48.

Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.06 EPS for the quarter, missing analysts' consensus estimates of $0.12 by ($0.06). The firm had revenue of $98.98 million for the quarter, compared to analyst estimates of $94.81 million. Artivion had a positive return on equity of 3.63% and a negative net margin of 5.49%. Sell-side analysts predict that Artivion will post 0.37 EPS for the current year.

Insider Buying and Selling

In other news, Director Anthony B. Semedo sold 2,600 shares of the business's stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $28.47, for a total value of $74,022.00. Following the completion of the sale, the director now directly owns 33,059 shares in the company, valued at $941,189.73. The trade was a 7.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Marshall S. Stanton sold 15,000 shares of the stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $29.50, for a total value of $442,500.00. Following the transaction, the senior vice president now owns 64,200 shares in the company, valued at $1,893,900. This trade represents a 18.94% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 72,954 shares of company stock valued at $2,108,525. Corporate insiders own 7.60% of the company's stock.

Hedge Funds Weigh In On Artivion

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC increased its stake in shares of Artivion by 236.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock worth $32,000 after purchasing an additional 786 shares in the last quarter. Legacy Advisors LLC acquired a new stake in Artivion in the 1st quarter worth about $28,000. MCF Advisors LLC increased its stake in Artivion by 109.3% during the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock worth $29,000 after buying an additional 614 shares in the last quarter. Arcadia Investment Management Corp MI purchased a new stake in Artivion during the 4th quarter worth approximately $43,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Artivion during the fourth quarter valued at approximately $64,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.